Igny­ta jumps on an FDA ‘break­through’ nod for en­trec­tinib; Ther­mo Fish­er buy­ing Patheon in $7.2B deal

Igny­ta has fresh rea­son to fo­cus more on en­trec­tinib, its TRK in­hibitor for the treat­ment of NTRK fu­sion-pos­i­tive tu­mors. The FDA has hand­ed out its break­through ther­a­py des­ig­na­tion for the pro­gram, help­ing ig­nite a surge in its share price ($RXDX, up 11%). The ther­a­py, now in Phase II, should re­ceive open door treat­ment by reg­u­la­tors, now charged with help­ing speed the drug through to an ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.